vs
Side-by-side financial comparison of ALNYLAM PHARMACEUTICALS, INC. (ALNY) and REPUBLIC AIRWAYS HOLDINGS INC. (RJET). Click either name above to swap in a different company.
ALNYLAM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($1.2B vs $1.1B, roughly 1.1× REPUBLIC AIRWAYS HOLDINGS INC.). Over the past eight quarters, ALNYLAM PHARMACEUTICALS, INC.'s revenue compounded faster (33.0% CAGR vs 3.9%).
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Republic Airways Holdings Inc. is an American airline holding company based in Indianapolis, Indiana. The company owns two regional airlines, Mesa Airlines and Republic Airways. Together the two airlines operate the world's largest fleet of Embraer 170 and Embraer 175 aircraft. The majority of the shares of company are owned by the mainline carriers that contract with Republic, American Airlines Group, Delta Air Lines, and United Airlines.
ALNY vs RJET — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $1.1B |
| Net Profit | $206.0M | — |
| Gross Margin | 82.2% | — |
| Operating Margin | 23.0% | 22.0% |
| Net Margin | 17.6% | — |
| Revenue YoY | 96.4% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $1.51 | $3.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.1B | $1.1B | ||
| Q3 25 | $1.2B | $90.7M | ||
| Q2 25 | $773.7M | $92.8M | ||
| Q1 25 | $594.2M | $94.7M | ||
| Q4 24 | $593.2M | $808.3M | ||
| Q3 24 | $500.9M | — | ||
| Q2 24 | $659.8M | $110.8M |
| Q1 26 | $206.0M | — | ||
| Q4 25 | $186.4M | — | ||
| Q3 25 | $251.1M | $-14.1M | ||
| Q2 25 | $-66.3M | $20.9M | ||
| Q1 25 | $-57.5M | $-58.6M | ||
| Q4 24 | $-83.8M | $97.8M | ||
| Q3 24 | $-111.6M | — | ||
| Q2 24 | $-16.9M | $-19.9M |
| Q1 26 | 82.2% | — | ||
| Q4 25 | 75.6% | — | ||
| Q3 25 | 84.2% | — | ||
| Q2 25 | 81.6% | — | ||
| Q1 25 | 88.2% | — | ||
| Q4 24 | 82.7% | — | ||
| Q3 24 | 83.6% | — | ||
| Q2 24 | 89.8% | — |
| Q1 26 | 23.0% | — | ||
| Q4 25 | 12.0% | 22.0% | ||
| Q3 25 | 29.5% | -10.1% | ||
| Q2 25 | -2.1% | -0.2% | ||
| Q1 25 | 3.0% | -60.4% | ||
| Q4 24 | -17.7% | 18.7% | ||
| Q3 24 | -15.4% | — | ||
| Q2 24 | 7.4% | -8.1% |
| Q1 26 | 17.6% | — | ||
| Q4 25 | 17.0% | — | ||
| Q3 25 | 20.1% | -15.6% | ||
| Q2 25 | -8.6% | 22.5% | ||
| Q1 25 | -9.7% | -61.9% | ||
| Q4 24 | -14.1% | 12.1% | ||
| Q3 24 | -22.3% | — | ||
| Q2 24 | -2.6% | -18.0% |
| Q1 26 | $1.51 | — | ||
| Q4 25 | $1.44 | $3.13 | ||
| Q3 25 | $1.84 | $-0.34 | ||
| Q2 25 | $-0.51 | $0.50 | ||
| Q1 25 | $-0.44 | $-1.42 | ||
| Q4 24 | $-0.66 | $2.42 | ||
| Q3 24 | $-0.87 | — | ||
| Q2 24 | $-0.13 | $-0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | $296.5M |
| Total DebtLower is stronger | — | $882.9M |
| Stockholders' EquityBook value | $1.1B | $1.3B |
| Total Assets | $5.1B | $3.3B |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $296.5M | ||
| Q3 25 | $1.5B | $38.7M | ||
| Q2 25 | $1.1B | $42.5M | ||
| Q1 25 | $1.0B | $54.1M | ||
| Q4 24 | $966.4M | $302.0M | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $968.5M | $16.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $882.9M | ||
| Q3 25 | — | $27.0M | ||
| Q2 25 | — | $28.2M | ||
| Q1 25 | — | $31.7M | ||
| Q4 24 | — | $752.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $287.7M |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $789.2M | $1.3B | ||
| Q3 25 | $233.9M | $-52.6M | ||
| Q2 25 | $250.6M | $-38.7M | ||
| Q1 25 | $115.4M | $-59.8M | ||
| Q4 24 | $67.1M | $1.1B | ||
| Q3 24 | $32.4M | — | ||
| Q2 24 | $-3.1M | $134.9M |
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.0B | $3.3B | ||
| Q3 25 | $4.9B | $158.9M | ||
| Q2 25 | $4.6B | $178.6M | ||
| Q1 25 | $4.2B | $215.0M | ||
| Q4 24 | $4.2B | $2.8B | ||
| Q3 24 | $4.2B | — | ||
| Q2 24 | $4.0B | $664.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.68× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALNY
| AMVUTTRA | $889.9M | 76% |
| GIVLAARI | $74.4M | 6% |
| OXLUMO | $51.3M | 4% |
| Royalty revenue | $49.0M | 4% |
| Regeneron Pharmaceuticals | $46.3M | 4% |
| Roche | $35.6M | 3% |
| ONPATTRO | $20.5M | 2% |
RJET
| United Airlines | $517.5M | 48% |
| Delta Air Lines | $409.7M | 38% |
| Other | $49.9M | 5% |
| Republic Airways Holdings Inc. | $42.2M | 4% |
| Other Airlines | $25.7M | 2% |
| LIFT Academy | $23.2M | 2% |
